8D39DD37-3B56-4788-B256-D924EBF2BD21
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.09855453350854139
- age_years
- 74
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.392
- WNT_BETA_CATENIN_SIGNALING+0.384
- G2M_CHECKPOINT+0.382
- MITOTIC_SPINDLE+0.373
- E2F_TARGETS+0.306
- MYC_TARGETS_V2+0.306
- CHOLESTEROL_HOMEOSTASIS+0.303
- MYC_TARGETS_V1+0.302
- ANDROGEN_RESPONSE+0.299
- DNA_REPAIR+0.273
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.328
- KRAS_SIGNALING_DN-0.323
- MYOGENESIS-0.278
- COAGULATION-0.264
- PANCREAS_BETA_CELLS-0.251
- SPERMATOGENESIS-0.233
- XENOBIOTIC_METABOLISM-0.173
- GLYCOLYSIS-0.144
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.142
- ESTROGEN_RESPONSE_LATE-0.133
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | D5E8379B-621C-4551-9B13-E63B1B068488 | — | — | 0.906 |
| 2 | 9198B2FA-637D-44B2-B6E8-24B5681737AA | — | — | 0.900 |
| 3 | SRR934799 | — | — | 0.893 |
| 4 | 84778027-9C8E-4364-9069-70D8B86D6916 | — | — | 0.875 |
| 5 | 07D10802-F79E-495E-B842-895C444CA439 | — | — | 0.874 |
| 6 | SRR934777 | — | — | 0.874 |
| 7 | EFEDAFE3-FF81-47ED-97F6-1193EA375D77 | — | — | 0.872 |
| 8 | 6990AABF-A5F4-4784-91FF-286A0EE6A618 | — | — | 0.870 |
| 9 | CBB97C4E-43C7-4257-A85E-1F72BA71EF91 | — | — | 0.868 |
| 10 | SRR934791 | — | — | 0.863 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.392 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.384 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.382 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.373 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.306 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.306 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.303 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.302 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.299 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.273 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.244 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.239 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.182 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.166 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.148 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.143 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.143 | Idelalisib | — uncovered |
| APOPTOSIS | 0.108 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.099 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.081 | Idelalisib | — uncovered |